{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:16:21Z","timestamp":1791245781106,"version":"4.1.0"},"reference-count":78,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Cancer Society and the Alberta Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library, PsycINFO, and EMBASE (2000\u20132024) for randomized controlled trials (RCTs) and non-randomized studies investigating psychedelic agents in cancer populations. Meta-analyses pooled RCTs of psilocybin or ketamine using random-effects models. Non-randomized studies were synthesized narratively. Risk of bias and evidence certainty were assessed via Cochrane ROB 2.0, NIH Before\u2013After tool, and GRADE. Eleven placebo-controlled RCTs and four single open-label studies were included. Meta-analysis of four ketamine RCTs (n = 354) showed large, rapid effects on depression\/anxiety (Hedges\u2019 g = \u22121.37, 95% CI: \u22122.66 to \u22120.08; I2 = 92%). Three psilocybin RCTs (n = 101) showed a large effect of psilocybin on alleviating depression (Hedges\u2019 g = \u22123.13, 95% CI: \u221210.04 to 3.77; I2 = 95%). MDMA and LSD trials suggested promise but lacked rigor. PAT may offer meaningful relief for cancer-related distress, though effects vary by therapeutic model and context. Oncology-specific trials are needed to standardize and scale for implementation.<\/jats:p>","DOI":"10.3390\/curroncol32070380","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T12:10:31Z","timestamp":1751285431000},"page":"380","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9981-4299","authenticated-orcid":false,"given":"Haley D. M.","family":"Schuman","sequence":"first","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Savard","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8256-5464","authenticated-orcid":false,"given":"Ra\u00e8f","family":"Mina","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Barkova","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2198-372X","authenticated-orcid":false,"given":"Hanna S. W.","family":"Conradi","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"},{"name":"Faculty of Arts, Department of Psychology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-0990","authenticated-orcid":false,"given":"Julie M.","family":"Deleemans","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-2085","authenticated-orcid":false,"given":"Linda E.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada"},{"name":"Faculty of Arts, Department of Psychology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/PPO.0000000000000395","article-title":"Integrative Approaches to Stress Management","volume":"25","author":"Carlson","year":"2019","journal-title":"Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.23.00293","article-title":"Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update","volume":"41","author":"Andersen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.23.00857","article-title":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","volume":"41","author":"Carlson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., and Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules, 26.","DOI":"10.3390\/molecules26102948"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2023.2278586","article-title":"Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis","volume":"57","author":"Bahji","year":"2025","journal-title":"J. Psychoact. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine","volume":"41","author":"Preller","year":"2021","journal-title":"J. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115886","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/08941939.2019.1710626","article-title":"Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients","volume":"34","author":"Liu","year":"2020","journal-title":"J. Investig. Surg."},{"key":"ref_11","first-page":"2266","article-title":"Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies","volume":"28","author":"Guo","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.20220835","article-title":"Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects","volume":"180","author":"Rosenblat","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ko, K., Knight, G., Rucker, J.J., and Cleare, A.J. (2022). Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.917199"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cpp.2880","article-title":"Psychologists\u2019 and psychotherapists\u2019 knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics","volume":"30","author":"Kucsera","year":"2023","journal-title":"Clin. Psychol. Psychother."},{"key":"ref_17","first-page":"Cd015383","article-title":"Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases","volume":"9","author":"Schipper","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1016\/j.jpainsymman.2022.01.024","article-title":"The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review","volume":"63","author":"Maia","year":"2022","journal-title":"J. Pain Symptom Manag."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-021-06027-y","article-title":"Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review","volume":"239","author":"Schimmers","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_22","unstructured":"National Heart Lung and Blood Institute (2025, February 10). Study Quality Assessment Tools, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients","volume":"323","author":"Shnayder","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J. Pain Symptom Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"key":"ref_26","unstructured":"PlotDigitizer (2025, January 27). PlotDigitizer: Version 3.1.6. PlotDigitizer.com 2025. Available online: https:\/\/plotdigitizer.com."},{"key":"ref_27","unstructured":"Schwarzer, G. (2025). Meta: An R Package for Meta-Analysis, 8.0-2, CRAN."},{"key":"ref_28","unstructured":"R Core Team (2023). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_29","unstructured":"RStudio Team (2020). RStudio: Integrated Development for R, RStudio, PBC."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.18632\/oncotarget.13743","article-title":"Ketamine rapidly relieves acute suicidal ideation in cancer patients: A randomized controlled clinical trial","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ren, Q., Hua, L., Zhou, X., Cheng, Y., Lu, M., Zhang, C., Guo, J., and Xu, H. (2022). Effects of a Single Sub-Anesthetic Dose of Ketamine on Postoperative Emotional Responses and Inflammatory Factors in Colorectal Cancer Patients. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.818822"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, H., Te, R., Zhang, J., Su, Y., Zhou, H., Guo, N., Chi, D., and Huang, W. (2024). Effects of a single subanesthetic dose of esketamine on postoperative subthreshold depressive symptoms in patients undergoing unilateral modified radical mastectomy: A randomised, controlled, double-blind trial. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-05753-9"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wolfson, P.E., Andries, J., Feduccia, A.A., Jerome, L., Wang, J.B., Williams, E., Carlin, S.C., Sola, E., Hamilton, S., and Yazar-Klosinski, B. (2020). MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75706-1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2023.0351","article-title":"Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Malone","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_42","unstructured":"FDA (2024). FDA Briefing Document: NDA 215455\u2014Midomafetamine (MDMA) for PTSD."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Bolstridge","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/pon.5771","article-title":"Evidence of psychological and biological effects of structured Mindfulness-Based Interventions for cancer patients and survivors: A meta-review","volume":"30","author":"Pedro","year":"2021","journal-title":"Psychooncology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the Bursting of the Psychedelic Hype Bubble","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuroimage.2019.06.053","article-title":"Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives","volume":"200","author":"Pallavicini","year":"2019","journal-title":"Neuroimage"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/02698811221140011","article-title":"A unified model of ketamine\u2019s dissociative and psychedelic properties","volume":"37","author":"Marguilho","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wolfson, P., and Vaid, G. (2024). Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1209419"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e180217","DOI":"10.1172\/JCI180217","article-title":"Licit use of illicit drugs for treating depression: The pill and the process","volume":"134","author":"Pacheco","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S1478951523001475","article-title":"Disruption as an opportunity or threat: A qualitative analysis of factors influencing the attitudes of experts in serious illness care toward psychedelic-assisted therapies","volume":"21","author":"Sholevar","year":"2023","journal-title":"Palliat. Support. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"pyaf023","DOI":"10.1093\/ijnp\/pyaf023","article-title":"Addressing blinding in classic psychedelic studies with innovative active placebos","volume":"28","author":"Aday","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future","volume":"42","author":"Goodwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","article-title":"Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant","volume":"44","author":"Wilkinson","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.annemergmed.2010.09.010","article-title":"Ketamine with and without midazolam for emergency department sedation in adults: A randomized controlled trial","volume":"57","author":"Sener","year":"2011","journal-title":"Ann. Emerg. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03019666","article-title":"Midazolam attenuates ketamine-induced abnormal perception and thought process but not mood changes","volume":"47","author":"Suzuki","year":"2000","journal-title":"Can. J. Anaesth."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat. Ment. Health"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences HHS Public Access","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol. Depend."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881121997099","article-title":"Cannabis-induced oceanic boundlessness","volume":"35","author":"Earleywine","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-012-2680-6","article-title":"High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens","volume":"223","author":"Reissig","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/02791072.2023.2258367","article-title":"Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health","volume":"55","author":"Urrutia","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","article-title":"Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies","volume":"80","author":"Palitsky","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/psymed.2023.0028","article-title":"A Systematic Review of Study Design and Placebo Controls in Psychedelic Research","volume":"2","author":"Wen","year":"2024","journal-title":"Psychedelic Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","article-title":"Ketamine and the Future of Rapid-Acting Antidepressants","volume":"17","author":"Riggs","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_68","unstructured":"FDA (2023). FDA Warns Patients and Health Care Providers About Potential Risks Associated with Compounded Ketamine Products, Including Oral Formulations, for the Treatment of Psychiatric Disorders."},{"key":"ref_69","first-page":"e242","article-title":"Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends","volume":"32","author":"Aslam","year":"2025","journal-title":"Am. J. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R., and Swainson, J. (2023). Use of ketamine for treatment resistant depression: Updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1283733"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/00048674251333577","article-title":"Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice","volume":"59","author":"Hussain","year":"2025","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_72","unstructured":"Mills, C. (2025, April 15). The Status of Ketamine Therapy in Canada. Available online: https:\/\/diplomatconsulting.com\/the-status-of-ketamine-therapy-in-canada\/."},{"key":"ref_73","unstructured":"Health, F.T. (2025, April 15). Ketamine Therapy Cost in Canada: Exploring Affordable Options. Available online: https:\/\/fieldtriphealth.ca\/ketamine-therapy-cost-in-canada\/."},{"key":"ref_74","unstructured":"Clinic, N.K.W. (2025, April 15). Ketamine Therapy Pricing. Available online: https:\/\/neuconnectionswellness.com\/ketamine-therapy-pricing\/."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kim, K., Yusuf, A., Sud, A., Persaud, N., Kirubarajan, A., Moller, M., Lloyd, T., and O\u2019Neill, B. (2024). Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0309911"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_77","unstructured":"Grof, S., and Halifax, J. (1978). The Human Encounter with Death, Souvenir Press."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int. Pharmacopsychiatry"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/380\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:49Z","timestamp":1760032909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":78,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070380"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070380","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}